| Features: treatment category |
| Chemotherapy is a treatment approach that uses drugs to target and kill rapidly dividing cells, primarily cancer cells. However, because many normal cells also divide quickly (such as those in the bone marrow, digestive tract, and hair follicles), chemotherapy can also affect these cells, leading to a range of side effects. Main Classes of Chemotherapy Agents and Examples Alkylating Agents: -work by adding alkyl groups to DNA, which interferes with the DNA’s structure and prevents replication. Examples: Cyclophosphamide, Ifosfamide, Melphalan, Chlorambucil, Busulfan. Anti-metabolites: -interfere with DNA and RNA synthesis by substituting for the normal building blocks of nucleic acids. Examples: Methotrexate, 5-Fluorouracil (5-FU), Cytarabine, Gemcitabine, 6-Mercaptopurine. Anti-microtubule Agents: -interfere with the structures that separate chromosomes during cell division (mitosis). Examples: Paclitaxel, Docetaxel, Vincristine, Vinblastine. Topoisomerase Inhibitors: -target the enzymes topoisomerase I and II, which control the changes in DNA structure required for replication. Examples: Etoposide (topoisomerase II inhibitor), Irinotecan (topoisomerase I inhibitor), Topotecan. Cytotoxic Antibiotics: -intercalate into DNA, inhibiting the replication of cancer cells. Examples: Doxorubicin, Daunorubicin, Bleomycin, Mitoxantrone. Platinum-Based Agents: -contain platinum and cause cross-linking of DNA, which interferes with DNA repair and replication. Examples: Cisplatin, Carboplatin, Oxaliplatin. Many chemotherapy agents exert their effects, at least in part, by inducing oxidative stress in cancer cells. They can increase ROS levels through several mechanisms: -Direct generation of free radicals. -Disruption of mitochondrial function, leading to increased production of ROS. -Interference with the cell’s antioxidant systems. -May want to avoid antioxidants 7 days bef ore and 7 days after chemo. Examples: NAC, Glutathione, Alpha Lipoic Acid, Vitamin E -anti-oxidants known to have pro-oxidant effects (like Quercetin, Curcumin, etc.) should not be taken 2-3 days before and after chemo -pro-oxidants known to bring good benefit to chemo can be continued during chemo. Examples are: Omega 3, Aremisia Annua, Silver NanoParticles. |
| Source: |
| Type: |
| Also called CCND1 Gatekeeper of Cell-Cycle Commitment The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression. Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer. Cyclin D1 is often found to be overexpressed in various cancers. Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression. Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer. In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response. |
| 1426- | Bos, | CUR, | Chemo, | Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer |
| - | in-vivo, | CRC, | NA | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | RKO | - | in-vitro, | CRC, | SW480 | - | in-vitro, | RCC, | SW-620 | - | in-vitro, | RCC, | HT-29 | - | in-vitro, | CRC, | Caco-2 |
| 5939- | Cela, | Chemo, | Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells |
| - | in-vitro, | Melanoma, | U266 | - | in-vitro, | Melanoma, | RPMI-8226 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:233 Target#:73 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid